CER Daily Newsfeed

Mirikizumab Demonstrates Superior Maintenance Efficacy in UC Treatment

(2/6, Skylar Jeremias, The American Journal of Managed Care) reports “Mirikizumab demonstrated superior maintenance efficacy over most therapies used to treat ulcerative colitis (UC), according to a Bayesian network meta-analysis to compare the efficacy and safety of biologics and small molecules for treating moderately to severely active UC.” Full

Flatiron Health and Exact Sciences Partner to Accelerate Clinical Evidence Generation for MRD Testing in Oncology

(2/5, Fred Pennic, HIT Consultant) reports “...The collaboration will leverage Flatiron’s innovative clinical research platform and extensive network of community oncology practices to study the test’s performance in diverse patient populations and real-world settings.” Full

Seizing Intellectual Property for Medicines Is Not a Path to Prosperity

(2/5, Kirsten Axelsen, Peter Pitts, AEI) comments “Since healthcare is among the biggest costs to the federal government, it is reasonable to evaluate what is spent on medical care and to consider policies and regulations to root out waste. However, the re-emergence of proposals to take away intellectual property for drugs is counterproductive; they do not reduce costs, and invoking these policies would inform investors in a leading US industry, that they should find a better place for their money.” Full